Clinical Trials Sponsored by MSD K.K.

Total 7506 results

Ono Pharmaceutical Co. Ltd
MSD K.K.

Completed

MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
Healios K.K.

Completed

Efficacy and Safety Study of HLCM051(MultiStem®) for Pneumonic Acute Respiratory Distress Syndrome (ONE-BRIDGE)

Respiratory Distress Syndrome, Adult

Japan
Mundipharma K.K.

Completed

Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients

Recurrent or Refractory PTCL

Japan
Mundipharma K.K.

Completed

Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

Japan
Mundipharma K.K.

Completed

Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies

Recurrent or Refractory T/NK-cell Malignancies

Japan
Healios K.K.

Completed

Treatment Evaluation of Acute Stroke for Using in Regenerative Cell Elements (TREASURE)

Stroke, Acute

Japan
AstraZeneca
AstraZeneca K.K.

Recruiting

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis (FORTUNA)

Nonalcoholic Steatohepatitis

United States, China, Korea, Republic of, Germany, Japan, Spain, Vietnam, Argentina, Colombia, Peru, Brazil, Malaysia, Taiwan, Thailand, Italy, Turkey, Hong Kong, Singapore, India, Mexico, Chile, Philippines, Portugal
Janssen Pharmaceutical K.K.

Recruiting

A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer (TAR-210)

Urinary Bladder Neoplasms | Receptors, Fibroblast Growth Factor

Japan
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Hematologic Malignancies

Japan
Janssen Pharmaceutical K.K.

Active, not recruiting

A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan (ProPuP)

Palmoplantar Pustulosis

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice

Ulcerative Colitis

Japan
Hamamatsu Photonics K.K.

Completed

Feature Detection Study for Validation of Hamamatsu NanoZoomer S360MD Digital Slide Scanner System

Pathology

United States
Janssen Pharmaceutical K.K.

Withdrawn

A Study of JNJ-75105186 in Healthy Japanese and Chinese Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)

Graft vs Host Disease

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-67953964 in Healthy Japanese Adult Male Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-40411813 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Different Doses of VAC52416 (ExPEC10V) in Japanese Adults

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Macitentan, in Healthy Japanese Male Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

Psoriasis

Japan
Janssen Pharmaceutical K.K.

Completed

A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Terminated

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Lymphocytic Leukemia

Japan
Janssen Pharmaceutical K.K.

Completed

Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia

Alzheimer's Disease

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Assess the Nicotine Pharmacokinetics, Tolerability and Safety With a New Oral Nicotine Replacement Product in Healthy Japanese Smokers

Healthy

Japan
Janssen Pharmaceutical K.K.

Withdrawn

Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)

Macular Degeneration | Geographic Atrophy | Visual Acuity

Japan
Janssen Pharmaceutical K.K.

Completed

A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.

Colitis, Ulcerative

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Safety and Immunogenicity of Different Doses of ExPEC4V (JNJ-63871860) in Healthy Japanese Adult Participants

Healthy

Japan
Solasia Pharma K.K.

Completed

A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)

Peripheral T-cell Lymphoma

Japan
Janssen Pharmaceutical K.K.

Completed

Safety, Pharmacokinetics, and Pharmacodynamics Study of Single Dose of CNTO 3649 in Healthy Adult Men and Multiple Doses of CNTO 3649 in Participants With Type 2 Diabetes Mellitus

Healthy | Diabetes Mellitus, Type 2

Japan
Janssen Pharmaceutical K.K.

Completed

A Long-term Efficacy and Safety Study of Tramadol Hydrochloride Plus Acetaminophen (JNS013) in Japanese Participants With Chronic Pain

Chronic Pain

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia

Schizophrenia

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

Japan
Janssen Pharmaceutical K.K.

Completed

A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder

Attention-Deficit / Hyperactivity Disorder

Japan
Janssen Pharmaceutical K.K.

Completed

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Alzheimer's Disease

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNS020QD in Patients With Chronic Pain

Chronic Pain

Japan
Janssen Pharmaceutical K.K.

Completed

A Single-Dose Pharmacokinetics and Safety Study of TMC278 in Healthy Adult Japanese Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
Janssen Pharmaceutical K.K.

Completed

A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia

Schizophrenia
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder

Attention-Deficit Hyperactivity Disorder

Japan
Janssen Pharmaceutical K.K.

Completed

A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome

Postoperative Pain | Postherpetic Neuralgia | Complex Regional Pain Syndromes (CRPS)

Japan
Janssen Pharmaceutical K.K.

Completed

A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection

Mycoses | Candidiasis | Neutropenia | Aspergillosis | Cryptococcosis | Histoplasmosis | Blastomycosis

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain

Pain | Cancer

Japan
Janssen Pharmaceutical K.K.

Completed

A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia

Schizophrenia

Japan
Janssen Pharmaceutical K.K.

Completed

Continuous Treatment Study of Topiramate in Migraine Participants

Migraine

Japan
Janssen Pharmaceutical K.K.

Completed

A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ 10229570-AAA to Evaluate Safety and Tolerability in Japanese Participants With Acne Vulgaris

Acne Vulgaris

Japan
Janssen Pharmaceutical K.K.

Completed

A Long-Term Study of JNS007ER in Patients With Schizophrenia

Schizophrenia
Janssen Pharmaceutical K.K.

Completed

An Exploratory Study of Tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back Pain

Osteoarthritis | Low Back Pain

3

Subscribe